Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VB10.16 plus Keytruda in first-line HPV16-positive recurrent/metastatic oropharyngeal HNSCC
2022-503055-26-00Phase 2Authorised
- Sponsor
- Nykode Therapeutics
- Start
- Oct 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 8
01
Overview
Phase 2, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) comparing VB10.16 + pembrolizumab with Pembrolizumab monotherapy (2 arms). Primary endpoints: Dose-limiting toxicities, Objective response rate and 1 more. Planned start Oct 2023; status: authorised.
02
Drugs
VB10.16pembrolizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2022-503055-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-503055-26-00.